TrialThe Lancet. Respiratory medicine2014

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.

Christopher E Brightling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.